Sign up to save your podcasts
Or
Share Dan Turner on vedolizumab in children with IBD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dan Turner on vedolizumab in children with IBD
Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.
Read the full article:
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS)
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv
View all episodes
By The Lancet GroupDan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.
Read the full article:
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS)
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv
More shows like The Lancet Gastroenterology & Hepatology in conversation with
View all
American Journal of Gastroenterology Author Podcasts
68 Listeners
The Lancet Voice
22 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners